Total Payments
$71,650
2024 Payments
$14,712
Companies
12
Transactions
58
Medicare Patients
848
Medicare Billing
$152,308
Payment Breakdown by Category
Other$41,269 (57.6%)
Consulting$22,721 (31.7%)
Travel$5,889 (8.2%)
Food & Beverage$1,771 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $41,269 | 13 | 57.6% |
| Consulting Fee | $22,721 | 10 | 31.7% |
| Travel and Lodging | $5,889 | 19 | 8.2% |
| Food and Beverage | $1,771 | 16 | 2.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $39,755 | 35 | $0 (2024) |
| GENZYME CORPORATION | $17,934 | 9 | $0 (2024) |
| Millennium Pharmaceuticals, Inc. | $7,622 | 3 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $1,625 | 1 | $0 (2021) |
| JAZZ PHARMACEUTICALS INC. | $1,590 | 1 | $0 (2022) |
| Regeneron Healthcare Solutions, Inc. | $1,568 | 2 | $0 (2024) |
| ARRAY BIOPHARMA INC | $700.00 | 1 | $0 (2024) |
| Novocure Inc. | $570.80 | 2 | $0 (2021) |
| Genentech USA, Inc. | $117.22 | 1 | $0 (2023) |
| Tempus AI, Inc | $78.08 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,712 | 19 | PFIZER INC. ($10,288) |
| 2023 | $18,188 | 11 | GENZYME CORPORATION ($15,856) |
| 2022 | $4,115 | 2 | PFIZER INC. ($2,525) |
| 2021 | $11,850 | 7 | PFIZER INC. ($9,580) |
| 2020 | $3,558 | 3 | PFIZER INC. ($3,558) |
| 2019 | $11,605 | 13 | PFIZER INC. ($11,605) |
| 2017 | $7,622 | 3 | Millennium Pharmaceuticals, Inc. ($7,622) |
All Payment Transactions
58 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/22/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $1,176.00 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $392.00 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2024 | PFIZER INC. | LORBRENA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $720.00 | General |
| Category: ONCOLOGY | ||||||
| 06/20/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $2,078.00 | General |
| Category: Oncology | ||||||
| 05/14/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Travel and Lodging | In-kind items and services | $60.30 | General |
| Category: ONCOLOGY | ||||||
| 05/13/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,275.00 | General |
| Category: ONCOLOGY | ||||||
| 05/01/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $72.53 | General |
| Category: ONCOLOGY | ||||||
| 04/30/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Travel and Lodging | In-kind items and services | $49.33 | General |
| Category: ONCOLOGY | ||||||
| 04/30/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Travel and Lodging | In-kind items and services | $35.00 | General |
| Category: ONCOLOGY | ||||||
| 04/30/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $24.63 | General |
| Category: ONCOLOGY | ||||||
| 04/30/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Travel and Lodging | In-kind items and services | $10.95 | General |
| Category: ONCOLOGY | ||||||
| 04/26/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Travel and Lodging | In-kind items and services | $379.05 | General |
| Category: ONCOLOGY | ||||||
| 04/24/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,625.00 | General |
| Category: ONCOLOGY | ||||||
| 04/23/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Travel and Lodging | In-kind items and services | $217.56 | General |
| Category: ONCOLOGY | ||||||
| 04/17/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $113.51 | General |
| Category: ONCOLOGY | ||||||
| 04/09/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Travel and Lodging | In-kind items and services | $701.14 | General |
| Category: ONCOLOGY | ||||||
| 03/11/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $3.70 | General |
| Category: Oncology | ||||||
| 02/15/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: ONCOLOGY | ||||||
| 01/24/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $78.08 | General |
| 11/28/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| 10/11/2023 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,741.00 | General |
| 10/11/2023 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $1,000.54 | General |
| 10/11/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $117.93 | General |
| 08/21/2023 | Genentech USA, Inc. | Lunsumio (Biological) | Food and Beverage | In-kind items and services | $117.22 | General |
| Category: BioOncology | ||||||
| 05/04/2023 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,741.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 333 | 723 | $113,467 | $35,401 |
| 2022 | 3 | 116 | 232 | $60,427 | $23,096 |
| 2021 | 4 | 170 | 425 | $123,475 | $48,221 |
| 2020 | 6 | 229 | 514 | $148,159 | $45,590 |
Total Patients
848
Total Services
1,894
Medicare Billing
$152,308
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 50 | 85 | $9,690 | $5,621 | 58.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 19 | 40 | $6,634 | $4,214 | 63.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 16 | 30 | $15,930 | $4,080 | 25.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $11,084 | $2,846 | 25.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 21 | $12,264 | $2,804 | 22.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 17 | 29 | $11,281 | $2,767 | 24.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 30 | $11,580 | $2,749 | 23.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $9,860 | $2,534 | 25.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 18 | 23 | $8,270 | $2,131 | 25.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 17 | 17 | $2,516 | $1,537 | 61.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 26 | 29 | $2,439 | $1,217 | 49.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 17 | $3,570 | $982.32 | 27.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 17 | 19 | $3,667 | $891.67 | 24.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 17 | 41 | $1,886 | $468.43 | 24.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 16 | 24 | $1,320 | $254.66 | 19.3% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 11 | 11 | $1,078 | $248.72 | 23.1% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2023 | 14 | 16 | $144.00 | $30.91 | 21.5% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 13 | 254 | $254.00 | $24.91 | 9.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 78 | 191 | $51,487 | $19,535 | 37.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 27 | 30 | $4,450 | $2,229 | 50.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 11 | 11 | $4,490 | $1,331 | 29.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 110 | 364 | $100,100 | $40,602 | 40.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 31 | 31 | $12,950 | $4,264 | 32.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 15 | 15 | $7,500 | $2,394 | 31.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 14 | 15 | $2,925 | $960.60 | 32.8% |
About Dr. Erin Bertino, MD
Dr. Erin Bertino, MD is a Hematology & Oncology healthcare provider based in Columbus, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/21/2007. The National Provider Identifier (NPI) number assigned to this provider is 1043355688.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Erin Bertino, MD has received a total of $71,650 in payments from pharmaceutical and medical device companies, with $14,712 received in 2024. These payments were reported across 58 transactions from 12 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($41,269).
As a Medicare-enrolled provider, Bertino has provided services to 848 Medicare beneficiaries, totaling 1,894 services with total Medicare billing of $152,308. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Columbus, OH
- Active Since 02/21/2007
- Last Updated 08/12/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1043355688
Products in Payments
- LORBRENA (Drug) $18,883
- BRAFTOVI (Drug) $10,264
- ALUNBRIG (Drug) $7,622
- SARCLISA (Biological) $2,078
- OPDIVO (Biological) $1,625
- ZEPZELCA (Drug) $1,590
- LIBTAYO (Biological) $1,568
- Optune (Device) $500.00
- Lunsumio (Biological) $117.22
- MEKINIST (Drug) $74.18
- NovoTTF-100L (Device) $70.80
- LUMAKRAS (Drug) $15.63
- PADCEV (Biological) $3.70
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Columbus
David Carbone, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $655,286
Hematology & Oncology $655,286
Spero Cataland, M.d, M.D
Hematology & Oncology — Payments: $249,112
Hematology & Oncology $249,112
Sam Penza, M.d, M.D
Hematology & Oncology — Payments: $247,603
Hematology & Oncology $247,603
Nadeem Ikhlaque, Md, MD
Hematology & Oncology — Payments: $124,067
Hematology & Oncology $124,067
Hannah Choe, M.d, M.D
Hematology & Oncology — Payments: $75,011
Hematology & Oncology $75,011
Seema Bhat, Md, MD
Hematology & Oncology — Payments: $58,066
Hematology & Oncology $58,066